After securing another major partnership, Factorial is closing in on bringing its “groundbreaking” all-solid-state EV battery platform to global markets. Factorial’s solid-state battery cells are ...

Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is expected to report fourth-quarter 2025 results soon. The Zacks Consensus ...

Cooling Fans are an essential resource for upgrading your Expedition from the Core Systems stage to Framework in ARC Raiders. You don't need too many, but tracking them down can be a challenge. This ...

The solid-state battery race is heating up. Factorial Energy, a Massachusetts-based start-up, plans to go public in mid-2026. The listing will provide $100 million in capital to advance its battery ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Billerica battery startup ...

Factorial, the start-up, said the listing would provide money that would help it bring new solid-state batteries to market as soon as 2027. By Jack Ewing Factorial Energy, which is developing advanced ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...

In mid-December 2025, an image (archived) circulated online purportedly showing U.S. President Donald Trump using a walker as a mobility aid. Keith Edwards, a Democratic political strategist, posted ...

Recursion Pharmaceuticals' work could change the way that drugs are developed. Its pipeline features some exciting candidates, and it's partnering with major drugmakers. However, Recursion still needs ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...